NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED

NeuroScientific Biopharmaceuticals Limited

NSB

AU0000012973

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 06:08:54 20/06/2024 BST			5-day change	1st Jan Change
0.039 ^AUD	+2.63%		-2.50%	-11.36%

06-11	Neuroscientific Biopharmaceuticals Secures US FDA Guidance for Glaucoma Medication	MT
03-20	NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	MT

Neuroscientific Biopharmaceuticals Limited Appoints T Abby Macnish as Co-Company Secretary

February 02, 2020 at 09:14 pm

NeuroScientific Biopharmaceuticals Limited announced that Abby Macnish has been appointed as co-Company Secretary, effective immediately.

Latest news about NeuroScientific Biopharmaceuticals Limited

Neuroscientific Biopharmaceuticals Secures US FDA Guidance for Glaucoma Medication	06-11	MT
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	03-20	MT
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors	12-04	CI
NeuroScientific Biopharmaceuticals CEO to Step Down	12-01	MT
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023	12-01	CI
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023	11-16	CI
Neuroscientific Biopharmaceuticals Limited Announces Board Changes	11-12	CI
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director	18/10/23	CI
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes	31/08/23	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study	14/03/23	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7%	05/12/22	MT
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"	04/12/22	CI
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12%	23/11/22	MT
NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO	22/11/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Management Changes	15/11/22	CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director	09/09/22	CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO	09/09/22	CI
Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial	06/09/22	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	29/08/22	CI
Neuroscientific Biopharmaceuticals Files Ethics Application for Phase 1 Trial of Neuroprotective Drug	12/07/22	MT
NeuroScientific Biopharmaceuticals Limited Announces Human Research Ethics Committee Submission for Phase I Clinical Trial	12/07/22	CI
Neuroscientific Recruits First Subject for Neurodegenerative Conditions Drug's Clinical Trial; Shares Rise 3%	30/06/22	MT

Chart NeuroScientific Biopharmaceuticals Limited

Duration

Period

Chart NeuroScientific Biopharmaceuticals Limited

More charts

NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED	-11.36%	3.67M
MODERNA, INC.	+35.14%	51.07B
IQVIA HOLDINGS INC.	-7.43%	38.78B
LONZA GROUP AG	+35.88%	38.61B
CELLTRION, INC.	-10.62%	27.32B
ICON PUBLIC LIMITED COMPANY	+11.63%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-17.77%	19.46B
UNITED THERAPEUTICS CORPORATION	+40.52%	13.58B
MEDPACE HOLDINGS, INC.	+30.70%	12.46B
BIO-TECHNE CORPORATION	-3.41%	11.75B